Clinical trials: Depression in Adults
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD
Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, three-period, three-treatment, six-sequence, crossover, balanced, single dose, dose proportionality study.
- Trial name
- NCT05416762
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg, Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Major Depressive Disorder
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 /…
- Trial name
- NCT00761306
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 74 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Post Traumatic Stress Disorder
ALTO-100 in MDD and/or PTSD
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
- Trial name
- NCT05117632
- Testing
- ALTO-100 PO tablet
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alto Neuroscience
Depression, Anxiety
Understanding the Efficacy of Mobile Apps as Intervention for Depression in Adults When Deployed as Part of Primary Care.
The clinical study is meant to optimize the mobile intervention, to develop a robust implementation plan for the mobile intervention within primary care, and to conduct an effectiveness trial, randomizing 128 participants in…
- Conditions
- Depression, Anxiety, Primary Health Care
- Trial name
- NCT03500536
- Testing
- IntelliCare
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Actualize Therapy
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 180 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of…
- Trial name
- NCT00250653
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- Sanofi
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD).
- Trial name
- NCT00831415
- Testing
- desvenlafaxine succinate sustained release tablets
- Where
- 17 sites in Japan
- Volunteers
- 304 people
- Sponsor
- Pfizer
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar I Disorder, Bipolar II Disorder
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- NCT06696755
- Testing
- Icalcaprant
- Where
- 33 sites in United States
- Volunteers
- 195 people
- Sponsor
- AbbVie
Major Depressive Disorder
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
- Trial name
- NCT00905424
- Testing
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Where
- 15 sites in United States
- Volunteers
- 246 people
- Sponsor
- Shire
Major Depressive Disorder
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.
- Trial name
- GATE-251 (NCT06547489)
- Testing
- Zelquistinel
- Where
- 34 sites in United States
- Volunteers
- 164 people
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Depressive Disorder, Major
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
- Trial name
- NCT01564862
- Testing
- vortioxetine (Lu AA21004), Duloxetine
- Where
- 92 sites in United States, Bulgaria and 5 more
- Volunteers
- 602 people
- Sponsor
- Takeda
Depression, Anxiety
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy…
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder
- Trial name
- NCT05604794
- Testing
- Ketamine-Assisted Psychotherapy (KAP)
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,806 people
- Sponsor
- Field Trip Health